Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

BACKGROUND AND HYPOTHESIS: Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD. METHODS: The EMPA-KIDNEY trial randomised 6609 patients with CKD (es...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nephrol Dial Transplant
Autori principali: Mayne, Kaitlin J, Sardell, Rebecca J, Staplin, Natalie, Judge, Parminder K, Zhu, Doreen, Sammons, Emily, Cherney, David ZI, Green, Jennifer B., Levin, Adeera, Pontremoli, Roberto, Hauske, Sibylle J., Emberson, Jonathan, Preiss, David, Landray, Martin J, Baigent, Colin, Wanner, Christoph, Haynes, Richard, Herrington, William G
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2024
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7616479/
https://ncbi.nlm.nih.gov/pubmed/39277784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfae203
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi